Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors
作者:Ádám Sipos、Eszter Szennyes、Nikolett Éva Hajnal、Sándor Kun、Katalin E. Szabó、Karen Uray、László Somsák、Tibor Docsa、Éva Bokor
DOI:10.3390/ph14040364
日期:——
ryl)methyl arene type compounds and studied several (C-β-D-glucopyranosylhetaryl)arene type GP inhibitors against SGLT. New compounds, such as 5-arylmethyl-3-(β-D-glucopyranosyl)-1,2,4-oxadiazoles, 5-arylmethyl-2-(β-D-glucopyranosyl)-1,3,4-oxadiazoles, 4-arylmethyl-2-(β-D-glucopyranosyl)pyrimidines and 4(5)-benzyl-2-(β-D-glucopyranosyl)imidazole were prepared by adapting our previous synthetic methods
寻求针对复杂,多因素疾病(例如糖尿病(DM))的新疗法的当前趋势是找到双重或什至多靶点抑制剂。在DM中,肾脏中的钠依赖性葡萄糖共转运蛋白2(SGLT2)和肝脏中的糖原磷酸化酶(GP)是经过验证的靶标。几种名为(glidozins)的(β-D-吡喃葡萄糖基芳基)甲基(杂)芳烃型化合物是针对SGLT2的市售药物。对于GP,存在低纳摩尔葡萄糖类似物抑制剂。本研究的目的是鉴定同时抑制SGLT和GP的双重作用化合物。为此,我们将SGLT2和GP抑制剂的结构活性关系扩展到了鲜为人知的(C -β-D-吡喃葡萄糖基杂芳基)甲基芳烃类型化合物,并研究了几种(C-β-D-吡喃葡萄糖基杂芳基)芳烃型SGLT抑制剂。新化合物,例如5-芳基甲基-3-(β-D-吡喃葡萄糖基)-1,2,4-恶二唑,5-芳基甲基-2-(β-D-吡喃葡萄糖基)-1,3,4-恶二唑,4通过适应我们以前的合成方法,制备了-芳基甲基-2-(β-